{'fraction_non_alphanumeric': 0.015089163237311385, 'fraction_numerical': 0.0, 'mean_word_length': 5.1344537815126055, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
BCG in cancer and leukemia treatment and prophylaxis-A review.

Five international oncology meetings crystallized the concept that the immune system plays a dominant role in the prevention and inhibition of neoplasia; that the cancer antigens are relatively weak, therefore eliminating weak or uneffective cellular immunity which is paramount in tumor rejection; that humoral antibodies against neoplastic antigens may block the cytotoxic action of T cells against the tumor cells. A number of agents have been found capable of stimulating the immune system (T-cell activation) but from a clinical standpoint BCG had had the widest application in a variety of tumors and leukemia. Thus the emphasis in this review will be on BCG.